Bringing together a patient's genetic test results and relating those to clinical, published knowledge
about pharmacogenomic relevance, explained O'Donnell, the portal gives physicians instant access to drug risks or benefits specific to an individual's genotype.
There were also lectures
about evidence - based dosing based on genotype, by the KNMP
Pharmacogenomics Working Group (Dr. Vera Deneer, den Haag, the Netherlands) and the European Medicine Agency
Pharmacogenomics Working Party (Dr. Norma Anwar, London, UK).
The 1st session included lectures related to clinical implementation of
Pharmacogenomics, featuring the keynote lecture by Prof. Julie Johnson (University of Florida, Tampa, FL, USA), followed by Prof. Markus Paulmichl (Paracelsus University, Salzburg, Austria), who provided an overview of the implementation of Pharmacogenomics in Austria and Prof. Magnus Ingelman - Sundberg (Karolinska Institutet, Stockholm, Sweden), who talked about sequencing of rare variants of pharmacoge
Pharmacogenomics, featuring the keynote lecture by Prof. Julie Johnson (University of Florida, Tampa, FL, USA), followed by Prof. Markus Paulmichl (Paracelsus University, Salzburg, Austria), who provided an overview of the implementation of
Pharmacogenomics in Austria and Prof. Magnus Ingelman - Sundberg (Karolinska Institutet, Stockholm, Sweden), who talked about sequencing of rare variants of pharmacoge
Pharmacogenomics in Austria and Prof. Magnus Ingelman - Sundberg (Karolinska Institutet, Stockholm, Sweden), who talked
about sequencing of rare variants of
pharmacogenomicspharmacogenomics interest.